Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2015

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2015’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview
Therapeutics Development
Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
AbbVie Inc.
Aprea AB
arGEN-X BV
Ariad Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
Biogenomics Limited
BioLineRx, Ltd.
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantargia AB
Celgene Corporation
Constellation Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
Eisai Co., Ltd.
EpiZyme, Inc.
Galena Biopharma, Inc.
Gamida Cell Ltd.
Hybrigenics S.A.
Ilyang Pharmaceutical Co., Ltd
Incyte Corporation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Juno Therapeutics Inc.
JW Pharmaceutical Corporation
KaloBios Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Lixte Biotechnology Holdings, Inc.
Mirna Therapeutics, Inc.
Natco Pharma Limited
Novartis AG
Onconova Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
OriBase Pharma
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Pharma Mar, S.A.
PharmaEssentia Corporation
Selvita SA
Shenogen Pharma Group Ltd.
Stemline Therapeutics, Inc.
Sun Pharma Advanced Research Company Ltd.
Synta Pharmaceuticals Corp.
Threshold Pharmaceuticals, Inc.
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABL-001 - Drug Profile
AIC-47 - Drug Profile
anagrelide hydrochloride CR - Drug Profile
APR-246 - Drug Profile
ARGX-110 - Drug Profile
azacitidine - Drug Profile
BC-2059 - Drug Profile
binimetinib - Drug Profile
BL-8040 - Drug Profile
BMS-833923 - Drug Profile
bosutinib - Drug Profile
BP-100101 - Drug Profile
CAN-04 - Drug Profile
Cell Therapy to Target GM-CSF for Oncology - Drug Profile
Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile
CPI-0610 - Drug Profile
CWP-291 - Drug Profile
D-12PGJ3 - Drug Profile
D-824 - Drug Profile
danusertib - Drug Profile
Dendritic Cell Therapy for Hematological Malignancies - Drug Profile
Dendritic Cell Therapy for Oncology - Drug Profile
Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile
Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile
DS-3032 - Drug Profile
E-6201 - Drug Profile
EPZ-5676 - Drug Profile
erismodegib - Drug Profile
ES-3000 - Drug Profile
ETC-027 - Drug Profile
ETC-219 - Drug Profile
evofosfamide - Drug Profile
flumatinib mesylate - Drug Profile
ganetespib - Drug Profile
Gene Therapy for Acute Myelocytic Leukemia and Chronic Myelocytic Leukemia - Drug Profile
guadecitabine - Drug Profile
HHGV-678 - Drug Profile
ilorasertib - Drug Profile
inecalcitol - Drug Profile
inotuzumab ozogamicin - Drug Profile
interferon alfa-2a (recombinant) - Drug Profile
interferon alfa-2b - Drug Profile
interferon alfa-2b (recombinant) - Drug Profile
ipilimumab - Drug Profile
JTCR-016 - Drug Profile
KB-004 - Drug Profile
LB-100 - Drug Profile
lurbinectedin - Drug Profile
MJ-05 - Drug Profile
MRX-102 - Drug Profile
MRX-34 - Drug Profile
napabucasin - Drug Profile
nivolumab - Drug Profile
NOV-120501 - Drug Profile
NRCAN-019 - Drug Profile
OPB-51602 - Drug Profile
ORB-0001 - Drug Profile
PF-114 - Drug Profile
ponatinib hydrochloride - Drug Profile
PRI-724 - Drug Profile
radotinib - Drug Profile
rebastinib tosylate - Drug Profile
rigosertib sodium - Drug Profile
ropeginterferon ALFA-2B - Drug Profile
ruxolitinib phosphate - Drug Profile
SEL-24B489 - Drug Profile
selinexor - Drug Profile
SL-401 - Drug Profile
SL-501 - Drug Profile
Small Molecule to Inhibit ADAR1 for Chronic Myeloid Leukemia - Drug Profile
Small Molecules to Inhibit Abl Tyrosine Kinase for CML - Drug Profile
Small Molecules to Inhibit BCR-ABL for CML - Drug Profile
Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile
Small Molecules to Inhibit BRCA2/Rad51 Interaction for Cancer - Drug Profile
SNG-1153 - Drug Profile
SNG-162 - Drug Profile
StemEx - Drug Profile
SUNK-706 - Drug Profile
TR-120 - Drug Profile
trametinib dimethyl sulfoxide - Drug Profile
Vaccine to Target Bcr-Abl Tyrosine Kinase for Chronic Myeloid Leukemia - Drug Profile
Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
Vaccine to Target WT1 for CML and AML - Drug Profile
Vaccine to Target WT1 for Oncology - Drug Profile
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2015
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Aprea AB, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Biogenomics Limited, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx, Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corporation, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co., Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics S.A., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corporation, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corporation, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mirna Therapeutics, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Limited, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Onconova Therapeutics, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OriBase Pharma, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar, S.A., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corporation, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita SA, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics, Inc., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Recent Pipeline Updates, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..1), H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..2), H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..3), H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..4), H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2015
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2015
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook